CJC-1295 no DAC Research Overview (also known as Modified GRF 1-29, Mod GRF 1-29, Sermorelin analog)
A synthetic analog of Growth Hormone Releasing Hormone (GHRH) without a Drug Affinity Complex, also called Modified GRF 1-29. It produces sharp, short-duration GH pulses that closely mimic the body's natural pulsatile secretion pattern. Frequently combined with GHRPs like Ipamorelin for synergistic GH release.
What Is CJC-1295 no DAC?
CJC-1295 without DAC — commonly called Modified GRF 1-29 — is a 29-amino-acid fragment of GHRH modified at positions 2, 8, 15, and 27 to resist enzymatic degradation. Unlike its DAC-bearing counterpart, it carries no albumin-binding complex, retaining a short half-life of approximately 30 minutes that produces a sharp, transient spike in GH secretion before rapid clearance.
Why Pulsatility Matters
Natural GH secretion is fundamentally pulsatile — the pituitary releases GH in discrete bursts, particularly during deep sleep and post-exercise. Continuous GH elevation (as produced by the DAC version) can desensitize pituitary receptors over time. Modified GRF 1-29 preserves pulsatile architecture, which some researchers consider more physiologically appropriate and potentially less prone to receptor downregulation with extended protocols.
Common Research Combinations
CJC-1295 no DAC is frequently combined with GHRP peptides such as Ipamorelin or GHRP-6. The rationale is synergistic: GHRH analogs prime and amplify the somatotroph pulse while GHRPs suppress somatostatin, the GH-inhibiting peptide. The combination can produce larger, cleaner GH pulses than either compound alone.
Comparison with DAC Version
Researchers choose the no-DAC form when pulse fidelity and natural GH rhythm preservation are the priority. They choose the DAC form when sustained baseline GH elevation and dosing convenience (once or twice weekly) are preferred.
Quick Reference
| Literature-Reported Dose Range | 100mcg (10 units if mixed at 100mcg/10 units) |
| Literature-Reported Frequency | 2-3 times daily for pulsatile release |
| Literature-Reported Cycle Length | 12-16 weeks continuous use |
| Literature-Reported Washout | Optional 2-4 week breaks to assess baseline |
| Storage | Refrigerate immediately, use within 30 days of reconstitution |
| Sites Reported in Studies | Subcutaneous: Lower abdomen (2 inches from navel), outer thigh, back of upper arm |
| Timing | Morning (upon waking), post-workout (if applicable), 30 minutes before bed |
Research Indications
Growth Hormone
Natural GH Pulse Restoration
Stimulates physiological growth hormone pulses that decline with age
IGF-1 Elevation
Increases insulin-like growth factor 1 levels through enhanced GH secretion
Pituitary Function Support
Maintains healthy pituitary-somatotroph axis without suppression
Anti-Aging
Muscle Mass Preservation
Supports lean muscle maintenance through enhanced protein synthesis
Bone Density Support
May help maintain bone mineral density through GH/IGF-1 pathway
Skin Elasticity
Potential improvements in skin thickness and collagen production
Recovery
Exercise Recovery
Enhances post-workout recovery through improved protein synthesis
Sleep Quality
May improve deep sleep stages when administered before bed
Injury Healing
Supports tissue repair through growth factor cascade activation
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Anti-Aging/Wellness | 100mcg | 2x daily (morning and bedtime) | SubQ |
| Body Composition | 100-150mcg | 3x daily (morning, post-workout, bedtime) | SubQ |
| Maximum GH Release | 200mcg | 2-3x daily with GHRP | SubQ |
| Sleep Enhancement | 100-200mcg | Once at bedtime | SubQ |
Timing
Morning (upon waking), post-workout (if applicable), 30 minutes before bed. Typical onset: gH elevation within 30 minutes, IGF-1 increases in 2-4 weeks, body composition changes in 6-12 weeks.
Peptide Interactions
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
Both are GHRH-pathway signals. They are alternatives rather than a validated combined exposure; concurrent use can confound GH/IGF-1 interpretation and is not recommended outside a specifically justified, monitored protocol.
Strong synergy when combined - GHRP-6 amplifies the GH pulse initiated by CJC-1295
Potent combination for maximizing growth hormone release through dual pathway activation
Can be combined but monitor for excessive GH elevation due to Hexarelin's potency
Never combine different CJC-1295 variants - choose based on desired release pattern
Different mechanisms - MK-677 provides continuous ghrelin stimulation while CJC-1295 offers pulsatile GHRH
Both are GHRH analogs that bind the same GHRH receptor. Combining them creates receptor competition and provides no meaningful additive benefit over using a single, appropriately dosed GHRH analog. Choose one GHRH analog per protocol.
Reported Research Timeline
01Day 1–7 (reported in cited studies): improved sleep quality, vivid dreams common due to enhanced REM sleep
02Week 2–4 (reported in cited studies): increased recovery from workouts, reduced DOMS, better pumps
03Week 4–8 (reported in cited studies): noticeable improvements in skin quality, minor body composition changes
04Week 8–12 (reported in cited studies): more significant lean mass gains, fat loss, improved joint comfort
05Week 12+ (reported in cited studies): continued gradual improvements in body composition and well-being
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Generally well-tolerated with minimal side effects at recommended doses
May cause temporary facial flushing or warmth for 5-10 minutes post-injection
Monitor blood glucose if diabetic - GH can affect insulin sensitivity
Not recommended for those with active cancer due to growth-promoting effects
Avoid if you have diabetic retinopathy or severe kidney disease
Seek Medical Attention If:
Persistent joint pain or carpal tunnel symptoms (indicates excessive GH)
Significant water retention or edema lasting more than 2 weeks
Unexplained headaches or vision changes
Extreme fatigue or lethargy (may indicate cortisol suppression)
Any signs of allergic reaction at injection sites
Quality Indicators
Verified Marker
Legitimate source with COA
Purchase from vendors providing certificates of analysis showing >98% purity
Verified Marker
Proper cold chain shipping
Peptide should arrive with ice packs or refrigerated shipping in hot weather
Verified Marker
Vacuum-sealed vials
Legitimate peptides create vacuum when reconstituted - water should be pulled in
Acceptable Range
Check expiration dates
Lyophilized peptide typically stable for 2 years if stored properly
Quality Concern
Pre-mixed solutions
Avoid pre-reconstituted products - peptide degrades rapidly in solution
Quality Concern
Discolored powder
White to off-white powder only - yellow or brown indicates degradation
Research Citations
Research Focus
Pulsatile GH release, Body composition, Recovery, Sleep quality, Natural GH rhythm preservation
Verified Vendors Carrying CJC-1295 no DAC
Frequently Asked Questions
What should researchers watch for with CJC-1295 no DAC?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with CJC-1295 no DAC?
Day 1–7 (reported in cited studies): improved sleep quality, vivid dreams common due to enhanced REM sleep
How is CJC-1295 no DAC typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →